Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia
Open accessThe DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index; none of the 70 sources its claims cite is checked for support yet.
Abstract
Background: Routine monitoring of anti-malarial drugs is recommended for early detection of drug resistance and to inform national malaria treatment guidelines. In Ethiopia, the national treatment guidelines employ a species-specific approach. Artemether-lumefantrine (AL) and chloroquine (CQ) are the first-line schizonticidal treatments for Plasmodium falciparum and Plasmodium vivax, respectively. The National Malaria Control and Elimination Programme in Ethiopia is considering dihydroartemisinin-piperaquine (DHA/PPQ) as an alternative regimen for P. falciparum and P. vivax. Methods: The study assessed the clinical and parasitological efficacy of AL, CQ, and DHA/PPQ in four arms. Patients over 6 months and less than 18 years of age with uncomplicated malaria mono-infection were recruited and allocated to AL against P. falciparum and CQ against P. vivax. Patients 18 years or older with uncomplicated malaria mono-infection were recruited and randomized to AL or dihydroartemisinin-piperaquine (DHA/PPQ) against P. falciparum and CQ or DHA/PPQ for P. vivax. Patients were followed up for 28 (for CQ and AL) or 42 days (for DHA/PPQ) according to the WHO recommendations. Polymerase chain reaction (PCR)-corrected and uncorrected estimates were analysed by Kaplan Meier survival analysis and per protocol methods. Results: A total of 379 patients were enroled in four arms (n = 106, AL-P. falciparum; n = 75, DHA/PPQ- P. falciparum; n = 142, CQ-P. vivax; n = 56, DHA/PPQ-P. vivax). High PCR-corrected adequate clinical and parasitological response (ACPR) rates were observed at the primary end points of 28 days for AL and CQ and 42 days for DHA/PPQ. ACPR rates were 100% in AL-Pf (95% CI: 96–100), 98% in CQ-P. vivax (95% CI: 95–100) at 28 days, and 100% in the DHA/PPQ arms for both P. falciparum and P. vivax at 42 days. For secondary endpoints, by day three 99% of AL-P. falciparum patients (n = 101) cleared parasites and 100% were afebrile. For all other arms, 100% of patients cleared parasites and were afebrile by day three. No serious adverse events were reported. Conclusion: This study demonstrated high therapeutic efficacy for the anti-malarial drugs currently used by the malaria control programme in Ethiopia and provides information on the efficacy of DHA/PPQ for the treatment of P. falciparum and P. vivax as an alternative option.
Overview
CoChat Summary
TL;DR
In an open-label, four-arm therapeutic efficacy study in Ethiopia, artemether-lumefantrine (AL), chloroquine (CQ), and dihydroartemisinin-piperaquine (DHA/PPQ) all showed high efficacy against uncomplicated *Plasmodium falciparum* and *P. vivax* at their respective follow-up endpoints. DHA/PPQ achieved 100% PCR-corrected ACPR at day 42 for both species, supporting it as an alternative regimen.
Key findings
- Among 379 enroled patients, PCR-corrected ACPR was 100% for AL against *P. falciparum* at day 28 (95% CI 96–100), 98% for CQ against *P. vivax* at day 28 (95% CI 95–100), and 100% for DHA/PPQ against both *P. falciparum* and *P. vivax* at day 42.
- By day 3, 99% of AL-treated *P. falciparum* patients (n = 101) cleared parasites and 100% were afebrile; in all other arms, 100% cleared parasites and were afebrile by day 3. No serious adverse events were reported.
- Among 50 day-0 *P. falciparum* samples sequenced, no *pfk13* artemisinin-resistance-associated mutants were observed; *pfmdr1* Y184F was present in 73%, N86Y in 2%, S1034N in 2%, and the NFD haplotype in 36/50 (75%).
- The 42-day ACPR for CQ against *P. vivax* was 82% overall (not a primary outcome), with site-specific values of 86.0% at Felegeselam and 97.7% at Arbaminch.
Methods
- Open-label, four-arm therapeutic efficacy trial at two Ethiopian health centres (Felegeselam, Pawe; Arbaminch), September–December 2017. Patients >6 months with uncomplicated mono-infection were enroled: those <18 years received AL for *P. falciparum* or CQ for *P. vivax*; those ≥18 years were randomized to AL or DHA/PPQ for *P. falciparum* and CQ or DHA/PPQ for *P. vivax*. Follow-up was 28 days for AL/CQ and 42 days for DHA/PPQ.
- Outcomes were analysed by per-protocol and Kaplan–Meier methods, with PCR correction to day 28 for AL and CQ. Laboratory methods included microscopy, haemoglobin measurement, parasite genotyping at CDC, and sequencing of *pfk13* and *pfmdr1*.
Limitations
- Stated by the authors: DHA/PPQ arms had lower-than-targeted enrolment because the study was not extended past the high transmission season; DHA/PPQ was studied only in adults ≥18 years, limiting generalizability to younger age groups; the study was powered per arm and not for between-arm comparisons; insufficient site-specific numbers required pooling data from two sites; adverse event data were not presented because ongoing symptoms were erroneously recorded as adverse events; the second AL dose was unobserved; and genotype investigation was limited to 50 samples without piperaquine or CQ resistance markers.
- Evident from the text: the trial was open-label, with no blinding described; PCR correction was only performed to day 28 for AL and CQ, so later CQ recurrences were not PCR-corrected; and the CQ 42-day ACPR of 82% was reported only as a non-primary outcome without confidence intervals.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
0 Valid · 1 Not valid · 28 Not checked · 55 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Asexual parasite clearance by day three was observed in all participants in all the arms by day three.”
§ Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No serious adverse events were reported.”
§ Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia > Abstract > Results
plainn = 379- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“High PCR-corrected adequate clinical and parasitological response (ACPR) rates were observed at the primary end points of 28 days for AL and CQ and 42 days for DHA/PPQ.”
§ Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia > Abstract > Results
plainn = 379- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In all four arms, the study participants were afebrile by day two.”
§ Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 28-day follow-up PCR-corrected ACPR for CQ against P. vivax was 98% (95% CI: 94–100)”
§ Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia > Results
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
23 more claims
Create a free account to see all 84 claims and to verify the 69 references still open.
- It may state two separate claims as one. 42
- Probably not a substantial claim. 23
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia > Methods > Molecular markers
“(N458Y, Y493H, R539T, I543T, C580Y, F446I, M476I, R561H, P553L)”
§ Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia > Results > Resistance markers
“(N456Y, Y493H, R539T, I543T, C580Y, F446I, M476I, R561H, P553L)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia > Results > Resistance markers
“One pfk13 non-synonymous mutation, E433D was observed in a day zero sample from Pawe.”
§ Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia > Results > Resistance markers
“| Wild type (no mutations detected) | 48 | 100 | 2 | 100 | 2 | 100 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia > Results
“Asexual parasite clearance by day three was observed in all participants in all the arms by day three.”
§ Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia > Results
“| Day 3 | 100 (99%) | 74 (100%) | 137 (100%) | 56 (100%) |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia > Results
“One (1%) asexual parasite on the DHA/PPQ against P. falciparum arm and three (2%) asexual parasites on the CQ arm against P. vivax was observed on day two, that eventually cleared on day three.”
§ Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia > Results
“| Day 2 | 97 (96%) | 74 (100%) | 137 (100%) | 56 (100%) |”
Citations
Cites
Artemisinin Resistance in Plasmodium falciparum Malaria
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808859 · Cited by 3,424
Uwimana, A., Legrand, E., Stokes, B. H., Ndikumana, J.-L. M., Warsame, M., Umulisa, N., Ngamije, D., Munyaneza, T., Mazarati, J.-B., Munguti, K., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1005-2 · Cited by 831
Harris, I., Sharrock, W. W., Bain, L. M., Gray, K.-A., Bobogare, A., Boaz, L., Lilley, K., Krause, D., Vallely, A., Johnson, M.-L., et al. (2010) · Malaria Journal · doi:10.1186/1475-2875-9-254 · Cited by 295
Assefa, A., Kassa, M., Tadese, G., Mohamed, H., Animut, A., & Mengesha, T. (2010) · Parasites & Vectors · doi:10.1186/1756-3305-3-1 · Cited by 267
Self-citationTaylor, W. R. J., Thriemer, K., von Seidlein, L., Yuentrakul, P., Assawariyathipat, T., Assefa, A., Auburn, S., Chand, K., Chau, N. H., Cheah, P. Y., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31285-1 · Cited by 178
Self-citationMicrosatellite Variation, Repeat Array Length, and Population History of Plasmodium vivax
Imwong, M., Sudimack, D., Pukrittayakamee, S., Osório, L., Carlton, J. M., Day, N., White, N. J., & Anderson, T. (2006) · Molecular Biology and Evolution · doi:10.1093/molbev/msj116 · Cited by 120
Okell, L. C., Cairns, M., Griffin, J. T., Ferguson, N. M., Tarning, J., Jagoe, G., Hugo, P., Baker, M., D’Alessandro, U., Bousema, T., et al. (2014) · Nature Communications · doi:10.1038/ncomms6606 · Cited by 91
Efficacy and safety of dihydroartemisinin-piperaquine
Myint, H. Y., Ashley, E. A., Day, N. P. J., Nosten, F., & White, N. J. (2007) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/j.trstmh.2007.05.018 · Cited by 89
A Unique Plasmodium falciparum K13 Gene Mutation in Northwest Ethiopia
Bayih, A. G., Getnet, G., Alemu, A., Getie, S., Mohon, A. N., & Pillai, D. R. (2016) · The American Society of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.15-0477 · Cited by 87
Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia
Teka, H., Petros, B., Yamuah, L., Tesfaye, G., Elhassan, I., Muchohi, S., Kokwaro, G., Aseffa, A., & Engers, H. (2008) · Malaria Journal · doi:10.1186/1475-2875-7-220 · Cited by 86
Self-citation
Research works printed but not linked: 1
- Ministry of Health Federal Democratic Republic of Ethiopia. Ethiopian Malaria Review Document. Addis Ababa, Ethiopia; 2020.
Cited by
Armando, C. J., Rocklöv, J., Sidat, M., Tozan, Y., Mavume, A. F., Bunker, A., & Sewe, M. O. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1162535 · Cited by 68
Laird, V. R., Plucinski, M. M., Venkatesan, M., Rondini, K. A., Randrianarivelojosia, M., Andriamananjara, M. N., Moonga, H., Ishengoma, D. S., Chidimatembue, A., Dimbu, P. R., et al. (2025) · Malaria Journal · doi:10.1186/s12936-025-05248-2 · Cited by 13
Self-citationMekasha, Y. T., Tegegne, A. A., Mashe, T., Girma, M., Hasen, G., & Belew, S. (2025) · Tropical Medicine & International Health · doi:10.1111/tmi.70072 · Cited by 10
Daka, D., Woldeyes, D., Golassa, L., Alemayehu, G. S., Zewde, Z., Tamiru, G., Misganaw, T., Massebo, F., & Wondale, B. (2024) · Malaria Journal · doi:10.1186/s12936-024-05087-7 · Cited by 10
Messele, A., Sutanto, E., Trimarsanto, H., Benavente, E. D., Barnes, M., Pearson, R. D., Siegel, S. V., Erko, B., Assefa, A., Getachew, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-47889-w · Cited by 6
Self-citation
Metadata
- Authors
- Assefa, A., Mohammed, H., Anand, A., Abera, A., Sime, H., Minta, A. A., Tadesse, M., Tadesse, Y., Girma, S., Bekele, W., Etana, K., Alemayehu, B. H., Teka, H., Dilu, D., Haile, M., Solomon, H., Moriarty, L. F., Zhou, Z., Svigel, S. S., Ezema, B., Tasew, G., Woyessa, A., Hwang, J., & Murphy, M.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Ethiopian Public Health Institute (ET)
- Centers for Disease Control and Prevention (US)
- ICAP Global Health (US)
- U.S. President's Malaria Initiative (US)
- World Health Organization (CH)
- Federal Ministry of Health (ET)
- Corresponding author
- Assefa, Ashenafi
- ORCID
- Venue
- Malaria Journal
- Published
- 2022-12-01
- Volume
- 21
- Issue
- 1
- Pages
- 359-359
- ISSN
- 1475-2875 (ISSN-L)
- PMC
- PMC9714156
- OpenAlex
- W4310640244
- Semantic Scholar
- 3b0feb8b3fc90c9fbb28a914bb3760f86fa8e84e
- Cited by
- 20
- References
- 43
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 6 · 2023: 4
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Update notices
- correction (2023-04-11)
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Malaria Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UNC Libraries
- Greater South Information System
- Funders
- Global Fund to Fight AIDS, Tuberculosis and Malaria
- World Health Organization
- Bundesministerium für Gesundheit
- Centers for Disease Control and Prevention
- President's Malaria Initiative
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- artemether-lumefantrine, dihydroartemisinin-piperaquine, chloroquine, Plasmodium falciparum, Plasmodium vivax, uncomplicated malaria, antimalarial drug efficacy, treatment failure, malaria treatment guidelines, Ethiopia, antimicrobial resistance surveillance
- MeSH terms
- Artemether, Artemether, Lumefantrine Drug Combination, Antimalarials, Chloroquine, Ethiopia, Humans, Piperazines, Plasmodium falciparum, Plasmodium vivax, Quinolines, Malaria, Falciparum, Malaria, Vivax, Artemisinins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia. https://app.cochat.ai/papers/10.1186/s12936-022-04350-z
- The paper
- Assefa, A., Mohammed, H., Anand, A., Abera, A., Sime, H., Minta, A. A., Tadesse, M., Tadesse, Y., Girma, S., Bekele, W., Etana, K., Alemayehu, B. H., Teka, H., Dilu, D., Haile, M., Solomon, H., Moriarty, L. F., Zhou, Z., Svigel, S. S., . . . Murphy, M. (2022). Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia. Malaria Journal. https://doi.org/10.1186/s12936-022-04350-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.